EGFR and lung adenocarcinoma: This study presents strong evidence that EGFR lowered expression in skin samples from stage IV lung adenocarcinoma patients treated with tyrosine kinase inhibitors could potentially be used as a surrogate to predict treatment response and avoid tumor biopsy‐related risks in this population.